Market Pressure From Employers and Consumers By early 2025: - 60% of large employers had added GLP-1 coverage - GLP-1 spending became one of the largest drivers of rising employer healthcare premiums - Companies began pushing for greater price transparency At the same time: - Consumer adoption accelerated 1 in 8 women and 1 in 20 men had used or were using a GLP-1 - GLP-1s went from a niche therapy to a central pillar of chronic disease management These changes were necessary because the millions of Americans living with obesity couldn't afford GLP-1 medications, even though they stood to benefit the most
The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis
Temporal trends revealed that discussions of adverse events increased significantly after notable events, including government approvals, viral media coverage, celebrity endorsements, and the expansion of Medicare coverage for weight loss medications
At Modern Medicine, wecouple Semaglutides with healthy eating plans and recommended exercise and havehelped patients loose an average of 1 to 2 lbs
Consistent with this finding, postmortem studies have reported markedly downregulated gene expression of antioxidant enzymes such as SOD1 and glutathione S-transferase in the hippocampus of BD patients, a finding that may relate to bipolar depression as the dominant phase [56]
(2019) Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer, BMC Cancer , 19 , 1020, doi: Huang, Z
